169 related articles for article (PubMed ID: 32613090)
1. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor.
Amin S; Baine M; Meza J; Alam M; Lin C
Clin Transl Radiat Oncol; 2020 Sep; 24():34-40. PubMed ID: 32613090
[TBL] [Abstract][Full Text] [Related]
2. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database.
Amin S; Baine M; Meza J; Alam M; Lin C
Radiat Oncol; 2020 Jun; 15(1):139. PubMed ID: 32493354
[TBL] [Abstract][Full Text] [Related]
3. The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database.
Amin S; Baine MJ; Meza JL; Lin C
Front Oncol; 2020; 10():1518. PubMed ID: 32983998
[No Abstract] [Full Text] [Related]
4. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
5. Association of Immunotherapy With Survival Among Patients With Brain Metastases Whose Cancer Was Managed With Definitive Surgery of the Primary Tumor.
Amin S; Baine MJ; Meza JL; Lin C
JAMA Netw Open; 2020 Sep; 3(9):e2015444. PubMed ID: 32902650
[TBL] [Abstract][Full Text] [Related]
6. The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do Not Receive Chemoradiation.
Amin SA; Baine MJ; Rahman I; Lin C
J Immunother; 2023 Jan; 46(1):14-21. PubMed ID: 36256124
[TBL] [Abstract][Full Text] [Related]
7. Patterns of Care and Outcomes of Adjuvant Chemoradiation for Node-Positive Pancreatic Adenocarcinoma.
Malakhov N; Lee A; Albert A; Lederman A; Byun J; Safdieh J; Schreiber D
J Gastrointest Cancer; 2020 Jun; 51(2):506-514. PubMed ID: 31236851
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database.
Seaton M; Hanna A; Boutros C; Hanna N
Ther Adv Med Oncol; 2019; 11():1758835919842438. PubMed ID: 31105777
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis.
Raoof M; Blakely AM; Melstrom LG; Lee B; Warner SG; Chung V; Singh G; Chen YJ; Fong Y
Cancer Med; 2019 Oct; 8(13):5881-5890. PubMed ID: 31414566
[TBL] [Abstract][Full Text] [Related]
10. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
11. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
12. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
13. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
[TBL] [Abstract][Full Text] [Related]
14. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
15. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
16. Optimal timing and treatment strategy for pancreatic cancer.
Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients.
Xiao Y; Chen W; Xie Z; Shao Z; Xie H; Qin G; Zhao N
BMC Cancer; 2017 Jan; 17(1):25. PubMed ID: 28056913
[TBL] [Abstract][Full Text] [Related]
18. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
19. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.
Adam MA; Nassour I; Hoehn R; Hlavin CA; Bahary N; Bartlett DL; Lee KKW; Zureikat AH; Paniccia A
Ann Surg Oncol; 2021 Jul; 28(7):3800-3807. PubMed ID: 33386547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
